Photocure $PHO.OL trade above last major resistance on US patent
Patent covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy.
Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer. Photocure has the intention to further investigate Hexvix for its therapeutic effect and the patent is a result of Photocure’s continued focus on securing intellectual property rights for its research results and pipeline activities.
The patent was issued on 11 February 2020 and will expire in December 2036.
* Neoadjuvant therapy: treatment (such as chemotherapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment
Photocure
PHO
IR news release: https://photocure.com/news/photocure-announces-new-us-patent-for-hexvix/
Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer. Photocure has the intention to further investigate Hexvix for its therapeutic effect and the patent is a result of Photocure’s continued focus on securing intellectual property rights for its research results and pipeline activities.
The patent was issued on 11 February 2020 and will expire in December 2036.
* Neoadjuvant therapy: treatment (such as chemotherapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment
Photocure
PHO
IR news release: https://photocure.com/news/photocure-announces-new-us-patent-for-hexvix/ 